Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

A German pharmaceutical company is moving its U.S. animal health headquarters to a new Johns Creek project. Boehringer ...

Established under President Joe Biden’s Inflation Reduction Act of 2022, the Medicare Drug Price Negotiation Program allows ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim strengthens footprintin Swiss biotech innovation hub. Basel, Switzerland, Thursday, 03.04.2025 – Today NBETherapeutics (NBE)a wholly owned subsidiary of Boehringer ...

Boehringer Ingelheim, a biopharmaceutical firm that manufactures medicine for humans and animals, has relocated to a ...

A pet vaccinated against rabies is safe from a rabid animal. Humans in the pet's family are also safe from rabies if the dog ...

driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer. Boehringer Ingelheim strengthens footprint in Swiss biotech innovation ...